This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Biogen Idec's performance against key rivals in the ethical pharmaceutical sector Assess the robust forecast sales contribution sourced from the relaunched Tysabri franchise in the multiple sclerosis market Evaluate the importance of royalty revenues delivered via rituximab, which will continue to support Biogen Idec's strong sales growth rate out to 2012.